Recent news highlights include corporate actions related to preferred stock dividends, regulatory approvals, and scientific publications supporting product dosing.

• Scilex Holding Company announced deferral of preferred stock dividend record date [N7].
• The company reported publication on GLOPERBA dosing adjustments in a peer-reviewed journal [N8].
• Scilex regained compliance with Nasdaq minimum closing bid price requirement [N1].
• Scilex won Health Canada approval for ELYXYB to treat acute migraine with or without aura [N1].
• FDA granted orphan drug status to Scilex’s colchicine for treatment of pericarditis [N1].
• Scilex announced FDA orphan drug designation for GLOPERBA for treatment of pericarditis [N1].

Scilex’s approved products address significant unmet needs in non-opioid pain management with differentiated delivery technologies and established market presence. The company’s pipeline candidates, including SEMDEXA and SP-103, have achieved key clinical milestones and regulatory designations that could support future approvals. Its focused commercial infrastructure and managed care capabilities facilitate product adoption and formulary access. The cryptocurrency treasury strategy represents a novel approach to asset management that could provide additional financial flexibility. Continued execution on commercialization and clinical development could enhance the company’s position in the pain management market.

Scilex faces challenges including significant net losses and limited liquidity, with a current ratio of 0.07 as of June 30, 2026, indicating potential financial constraints. The company’s reliance on a limited number of commercial products and ongoing clinical development programs exposes it to regulatory, clinical, and market risks. The cryptocurrency treasury strategy introduces additional risk related to market volatility and regulatory uncertainty. Competition in the pain management space is intense, and failure to achieve regulatory approvals or commercial uptake for pipeline candidates could impact growth prospects. Dependence on third-party manufacturers and distributors also presents operational risks.

Scilex’s moat derives from its portfolio of FDA-approved non-opioid pain management products addressing large markets with unmet needs, including neuropathic pain, migraine, and gout. Its proprietary delivery technologies, such as the novel adhesion and drug delivery system in ZTlido and the liquid oral formulation of colchicine in GLOPERBA, provide differentiation. The company’s clinical-stage candidates, including SEMDEXA with fast track designation and completed pivotal trials, add potential future value. Exclusive licensing agreements and manufacturing partnerships, along with a dedicated and experienced sales force targeting specialized physician groups, support market access and product uptake. Additionally, patent protections and regulatory exclusivities for its products and candidates contribute to barriers to entry.

• Financial and Liquidity Risk: As of June 30, 2026, Scilex reported a net loss of $114.99 million and a current ratio of 0.07, indicating limited liquidity which may constrain operational flexibility and require additional financing.
• Regulatory and Clinical Development Risk: The company’s pipeline candidates, including SEMDEXA, SP-103, and SP-104, face inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance.
• Market Competition and Commercial Execution Risk: Scilex operates in competitive pain management markets with established products; successful commercialization depends on effective sales, marketing, and managed care contracting.
• Cryptocurrency Treasury Strategy Risk: Investment in cryptocurrencies exposes the company to market volatility, regulatory changes, and custodial risks that could affect treasury asset values and financial stability.
• Dependence on Third-Party Manufacturers and Distributors: Scilex relies on third parties for manufacturing and distribution, which may pose risks related to supply chain disruptions, quality control, and contractual terms.

• Scilex Holding Co is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain treatment [S1].
• The company’s commercial products include ZTlido (lidocaine topical system) 1.8%, approved by FDA for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an FDA-approved oral solution for acute migraine treatment; and GLOPERBA, an FDA-approved liquid oral colchicine for gout prophylaxis launched in June 2024 [S1].
• Scilex has three product candidates: SP-102 (SEMDEXA), a viscous gel corticosteroid for epidural injections to treat sciatica with completed Phase 3 study; SP-103, a triple-strength lidocaine topical system for acute pain with completed Phase 2 trial; and SP-104, a low-dose delayed-release naltrexone hydrochloride capsule for fibromyalgia with completed Phase 1 trials [S1].
• The company’s commercial strategy includes maximizing ZTlido uptake via a dedicated sales force targeting over 3,500 physicians, direct-to-patient marketing, and managed care contracting with major payors and pharmacy benefit managers [S1].
• ELYXYB commercialization leverages existing sales infrastructure with efforts to educate the market, broaden access, and negotiate payer contracts [S1].
• GLOPERBA commercialization targets approximately 3,000 healthcare providers with education on dose adjustments and payer negotiations to increase access for patients with comorbidities and GI intolerance [S1].
• SEMDEXA development targets the first FDA-approved epidural steroid injection for sciatica, with fast track designation and completed pivotal Phase 3 study showing achievement of primary and secondary endpoints; a second Phase 3 study initiated in September 2025 [S1].
• SP-103 development focuses on a triple-strength lidocaine topical system for acute pain, with Phase 2 results showing safety and tolerability; it has FDA Fast Track status [S1].
• SP-104 is developed for fibromyalgia, addressing shortcomings of existing therapies with completed Phase 1 studies characterizing pharmacokinetics and safety [S1].
• Scilex has adopted a cryptocurrency treasury strategy to invest in bitcoin, Ethereum, BNB, Doge, and other blockchain-linked cryptocurrencies as long-term treasury assets, with plans to grow holdings and generate revenue via staking and yield activities [S1].
• Financial snapshot as of 2026-06-30 from SEC filings: revenue of $7.64 million, net loss of $114.99 million, basic and diluted EPS of -$16.65, cash and equivalents of $566,000, current assets of $36.24 million, current liabilities of $512.24 million, current ratio of 0.07, and cash ratio of 0 [S2].
• The company’s sales force comprises over 30 experienced representatives focused on pain management products, targeting physicians treating PHN, migraine, gout, sciatica, and acute pain [S1].
• ZTlido had approximately 5.6% market share of the lidocaine patch prescription market in covered U.S. territories as of December 31, 2025 [S1].
• Scilex’s distribution network includes national and regional wholesalers and pharmacies, with contracts with major distributors such as McKesson, Cardinal Health, and AmerisourceBergen [S1].
• The company has patient assistance programs and managed healthcare account executives to support formulary access and patient affordability for its products [S1].
• Recent news includes announcements of deferral of preferred stock dividend record date, publication on GLOPERBA dosing adjustments, regaining Nasdaq compliance, Health Canada approval for ELYXYB, and FDA orphan drug designations for colchicine and GLOPERBA [N7][N8].